8. ハンチントン病 Huntington disease Clinical trials / Disease details

臨床試験数 : 242 / 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159

5 trials found

diseases per page:

Showing 1 to 5 of 5 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01411163 (ClinicalTrials.gov)	April 2010	4/8/2011	Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability	Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability	Huntington's Disease	Drug: Creatine monohydrate	Massachusetts General Hospital	National Institutes of Health (NIH)	Completed	26 Years	N/A	Both	24	Phase 2	United States
2	NCT00712426 (ClinicalTrials.gov)	September 2009	8/7/2008	Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)	Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)	Huntington's Disease	Drug: Creatine Monohydrate;Drug: Placebo	Massachusetts General Hospital	University of Rochester;National Center for Complementary and Integrative Health (NCCIH)	Terminated	18 Years	N/A	Both	553	Phase 3	United States;Australia;Canada;New Zealand
3	NCT01411150 (ClinicalTrials.gov)	May 2009	4/8/2011	Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study	Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study	Huntington's Disease	Drug: Creatine Monohydrate	Massachusetts General Hospital	National Institutes of Health (NIH)	Completed	26 Years	N/A	Both	38	Phase 2	United States
4	NCT00592995 (ClinicalTrials.gov)	December 2007	28/12/2007	Creatine Safety and Tolerability in Premanifest HD: PRECREST	Creatine Safety and Tolerability in Premanifest HD: PRECREST	Huntington Disease	Drug: Creatine monohydrate;Drug: Placebo	Massachusetts General Hospital	NULL	Completed	26 Years	N/A	Both	64	Phase 2	United States
5	NCT01412151 (ClinicalTrials.gov)	April 2005	5/8/2011	Creatine Safety & Tolerability in Huntington's Disease	Creatine Safety & Tolerability in Huntington's Disease (CREST-X): A Single-Center, Open-Label, Long- ...	Huntington's Disease (HD)	Drug: Creatine monohydrate	Massachusetts General Hospital	NULL	Completed	18 Years	N/A	All	10	Phase 2	United States

First Previous1Next Last